MetaCap

Greenland Mines Ltd. (GRML)

NASDAQ: GRMLHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

2.99+0.08 (+2.75%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

GRML stock chart

Technical analysis

Key statistics

All statistics
Market cap
$44.31M
EPS (TTM)
-$9.74
52-week range
2.75 – 37.00
Day range
2.75 – 3.10
Volume / Avg
857.85K / 8.93M
Beta
—

52-week range

$2.75$37.00

GRML stock today

Shares of Greenland Mines (GRML) finished higher on Nov 20 at $2.99, a gain of 2.75% or $0.08 per share, versus the S&P 500's 3.70% decline. Trading was light, with 857.85K shares changing hands, about 10% of the average daily volume. At this level, GRML sits near the bottom of its 52-week range of $2.75 to $37.00: 91.9% below the high, set on Mar 4, 2026 and 8.7% above the low.

GRML is down 79.3% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 87.1%. Greenland Mines has posted a net loss over the last twelve months (EPS of -$9.74), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Greenland Mines

Company profile

Greenland Mines Ltd engages in the cell and gene therapy, and natural resources businesses. The company primarily explores palladium, gold, and platinum deposits. It focuses on the exploration and development of Skaergaard project located in Southeast Greenland and the Sarartoq neodymium-praseodymium (Nd-Pr) rare earths project in Southwest Greenland.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. Joseph A. Sinkule Pharm.D.
Headquarters
Charlotte, NC
Employees
5
IPO year
2022

Financial highlights

Full financials

Greenland Mines reported a net loss of $10.6 million, compared with a loss of $6.2 million a year earlier. Diluted earnings per share came in at -$0.22.

Greenland Mines annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022
Revenue————
Growth————
Net income$-10.55M$-6.15M$-707.46K$1.23M
EPS (diluted)$-0.22$-0.32$-0.05—

Analyst forecast

Forecast

Consensus (1 analysts)

none

Avg. price target

$110.00+3578.93%

  • Strong buy 0
  • Buy 1
  • Hold 0
  • Sell 0
  • Strong sell 0

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 16, 2026
EPS actual vs est.
$-2.51 vs —

GRML news

All GRML news

Greenland Mines peers

Health Care sector
GRML peer companies
CompanyPrice% ChgMarket capCompare
ELOXEloxx Pharmaceuticals Inc.10.69-1.75%$43.69Mvs GRML
INKTMiNK Therapeutics Inc.8.02-6.85%$41.17Mvs GRML
ELUTElutia Inc. Class A0.9001+11.12%$39.96Mvs GRML
IMAImageneBio Inc.3.920.00%$48.83Mvs GRML
TILInstil Bio Inc.5.23-5.77%$35.47Mvs GRML
AVXLAnavex Life Sciences Corp.0.5915-11.39%$54.83Mvs GRML
CGTXCognition Therapeutics Inc.0.5822-3.06%$55.37Mvs GRML
OKYOOKYO Pharma Limited1.07-7.76%$56.15Mvs GRML

Indexes, lists and sector

Greenland Mines stock FAQ

What is Greenland Mines's stock price today?

GRML last traded at $2.99 as of Nov 20, 4:00 PM EST, up 2.75% on the day. Prices are delayed at least 15 minutes.

Does Greenland Mines pay a dividend?

No. Greenland Mines does not currently pay a regular cash dividend.

Who is Greenland Mines's CEO?

Dr. Joseph A. Sinkule Pharm.D. is the chief executive officer of Greenland Mines Ltd., which has about 5 employees.

Has GRML ever split its stock?

Yes. The most recent GRML stock split was a 1-for-50 split on Aug 24, 2026.

What is the GRML 52-week high?

The 52-week high for GRML is $37.00 and the 52-week low is $2.75. The stock is currently 91.9% below its high.

Compare GRML